{
  "docId": "019dd923-622c-750b-8b98-17b017c6aac8",
  "docSlug": "384ff8288d23",
  "documentTitle": "Acutus Medical Inc. (AFIB)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 27,
  "pageCount": 29,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "This is a text-heavy research note slide summarizing the investment case.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-17b017c6aac8/27",
  "deckHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8#slide-27",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "At Atricure’s valuation, Acutus shares would be worth $28, more than double their current price, and still offer the prospect of multiplying several times over as AcQMap becomes the standard of care in complex arrhythmias.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-fb8f-761b-afce-53f401267ecf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "share price target: $28",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-fb8f-761b-afce-574e8c160d7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.764,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "paragraph",
      "text": "non-contact mapping technology can change the ablation paradigm – dramatically increasing procedural effectiveness, and making the procedure faster, simpler, and more efficient for its practitioners.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fdac6bc-0edb-47c6-a87c-c6bf2582d2fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.265,
        "w": 0.764,
        "x": 0.118,
        "y": 0.165
      },
      "kind": "paragraph",
      "text": "Despite operating in a multi-billion dollar market growing at high double digit rates, Acutus trades at about 8x the next twelve months’ consensus revenue estimates, and at just 5x our 2022 estimate of $76 million in revenues, a valuation on par with mega-cap medical device companies like Boston Scientific and Medtronic, and a steep discount to more rapidly growing upstarts. Atricure, the only other public company exclusively dedicated to ablation devices, trades at more than 11x consensus estimates for its 2022 revenues despite the fact that its surgical ablation end markets are growing much more slowly than the catheter ablation market, and its core products are existentially threatened by catheter ablation advances. At Atricure’s valuation, Acutus shares would be worth $28, more than double their current price, and still offer the prospect of multiplying several times over as AcQMap becomes the standard of care in complex arrhythmias. Acutus’s singularly unique offering in the context of its $480 million market cap presents an investment opportunity that can aptly be described as electric.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acd0ea74-9f6e-41ab-b8e3-ab46eb9a22b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "26301499-db59-4e9f-b424-8df78499d21a",
      "evidence": "non-contact mapping technology can change the ablation paradigm – dramatically increasing procedural effectiveness, and making the procedure faster, simpler, and more efficient for its practitioners",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}